Margaret Rosenfeld, MD, MPH

Professor
Department of Pediatrics, University of Washington School of Medicine

Poster(s):

• (4) Role of Hyperglycemia in Cystic Fibrosis Pulmonary Exacerbations
  Thursday, November 3, 2022

  12:00 PM – 12:40 PM ET

• (41) Association of Pseudomonas aeruginosa Infection Stage with Lung Function Trajectory In Children with CF>
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (119) Pulmonary Exacerbation Antibiotic Treatment for Children with Cystic Fibrosis and Polymicrobial Infection
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (142) The STOP PEDS Pilot Study of Oral Antibiotic Timing in Pediatric CF Pulmonary Exacerbations
  Thursday, November 3, 2022

  12:00 PM – 12:40 PM ET

• (173) Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in children with cystic fibrosis: The Pediatric PROMISE study
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (182) A Qualitative Needs Assessment of People with CF and Research Coordinators to Inform Future Clinical Trials Incorporating Home Spirometry as an Endpoint
  Thursday, November 3, 2022

  12:00 PM – 12:40 PM ET

• (224) Elexacaftor/Tezacaftor/Ivacaftor alters Gastrointestinal Symptoms and Inflammation: Report of PROMISE Peds GI
  Thursday, November 3, 2022

  12:00 PM – 12:40 PM ET

• (548) A locus near ICOS is a genetic modifier for risk of Mycobacterium avium complex airway infection in persons with cystic fibrosis.
  Thursday, November 3, 2022

  12:00 PM – 12:40 PM ET

• (693) A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 2 Through 5 Years of Age with Cystic Fibrosis and at Least One F508del Allele
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET